Category Archives: Biotechnology

Post Registrar

What Should Investors Make Of The Trading Chart Of Puma Biotechnology, Inc. (PBYI)? NY Stock News Puma Biotechnology, Inc. (PBYI) is now trading with a very clear set of technicals. Taken together they paint a very compelling picture of how investors and traders should be approaching PBYI. Technical charts are very important tools for traders, but ... Puma Biotechnology Inc (PBYI) Upgraded to "Buy" by Zacks Investment ResearchThe Cerbat Gem Stock to Keep Your Eyes on: Puma Biotechnology (NASDAQ:PBYI)Post Registrar Puma Biotechnology, Inc. performed Very Well with a change of 2.07% in the Last TradeFree Observer Sports Perspectives -StreetInsider.com -Stock Rover all 24 news articles »

The rest is here:
What Should Investors Make Of The Trading Chart Of Puma Biotechnology, Inc. (PBYI)? - NY Stock News

Cellect Biotechnology

Kfar Saba, Israel-based Cellect Biotechnology Ltd's stock finished Monday's session 2.84% lower at $8.56 with a total trading volume of 27,234 shares. Over the previous three months and since the start of this year, the Company's shares have advanced 34.80% and 177.02%, respectively. The stock is trading above its 200-day moving average by 53.25%. Moreover, shares of Cellect Biotech, which focuses on developing solutions for immune system regeneration in Israel, have a Relative Strength Index (RSI) of 34.93.

On May 23rd, 2017, Cellect Biotech announced that David Braun, Head of Merck Group's Medical Device Business, is joining the Company's Scientific and Medical Advisory Board. Mr. Braun has held multiple additional senior-level executive positions at leading biotech and high-tech companies, ranging from global Fortune 500 corporations to growth-oriented organizations, including Biosafe S.A., a stem cell separation leader recently acquired by GE, Newell Brands, Logitech, Chiaro Networks, and Elbit Systems. Your complete research report on APOP can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=APOP

BioDelivery Sciences

Shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. declined 4.26%, ending yesterday's session at $2.25 with a total trading volume of 405,472 shares. The stock has gained 25.00% in the past month, 9.76% in the previous three months, and 28.57% on an YTD basis. The Company's shares are trading 17.71% above their 50-day moving average and 8.95% above their 200-day moving average. Moreover, shares of BioDelivery Sciences, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have an RSI of 56.49.

On May 26th, 2017, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $4 per share.

On June 01st, 2017, BioDelivery Sciences announced that Dr. Mark A. Sirgo, President and CEO, will present at the Jefferies 2017 Healthcare Conferenceon June 06th, 2017, at9:30 a.m. ET at the Grand Hyatt in New York City. Dr. Sirgo will focus on progress with commercialization efforts and strategic initiatives supporting BELBUCA(buprenorphine) buccal film (CIII), as well as provide an update on BUNAVAIL(buprenorphine and naloxone) CIII.A free report on BDSI is just a click away at: http://dailystocktracker.com/registration/?symbol=BDSI

BioLine Rx

On Monday, Jerusalem, Israel headquartered BioLine Rx Ltd's stock saw a decline of 2.51%, to close the day at $0.82. A total volume of 177,369 shares was traded. The Company's shares are trading 8.55% below their 50-day moving average. Additionally, shares of BioLine Rx, which engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs, have an RSI of 41.26.

On May 18th, 2017, research firm Maxim Group upgraded the Company's stock rating from 'Hold' to 'Buy' while revising its previous target price from $1 a share to $3 a share.

On June 01st, 2017, BioLine Rx announced that Genentech, a member of the Roche Group, has filed a total of three, regulatory submissions required to commence Phase-1b trials for BL-8040 in combination with atezolizumab (Tecentriq), Genentech's anti-PDL1 cancer immunotherapy, for the treatment of patients with solid tumors. The trials for pancreatic, gastric, and non-small cell cancer are expected to commence during Q2 2017 after receipt of regulatory approval. Sign up for your complimentary research report on BLRX at: http://dailystocktracker.com/registration/?symbol=BLRX

Benitec Biopharma

Shares in North Sydney, Australia headquartered Benitec Biopharma Ltd ended the day 4.02% lower at $2.39. A total volume of 50,220 shares was traded. The stock has gained 56.21% since the start of this year. The Company's shares are trading above their 200-day moving average by 16.27%. Furthermore, shares of Benitec Biopharma, which develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference in Australia, the UK, and the US, have an RSI of 43.99. Register for free on DailyStockTracker.com and download the latest research report on BNTC at: http://dailystocktracker.com/registration/?symbol=BNTC

--

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

DST has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: contact@dailystocktracker.com Phone number: (207)-331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Read more here:
Biotech Stock Performance Review -- Cellect Biotechnology ... - PR Newswire (press release)

A Toronto Stock Exchange (TSX) logo is seen in Toronto November 9, 2007. (Mark Blinch / Reuters) A Toronto Stock Exchange (TSX) logo is seen in Toronto November 9, 2007. (Mark Blinch / Reuters) Subscribers Only

Sean Silcoff

OTTAWAThe Globe and Mail

Published Sunday, Jun. 04, 2017 3:36PM EDT

Last updated Sunday, Jun. 04, 2017 3:39PM EDT

The Canadian biotechnology business is a picture of good health.

On Friday, management of Vancouver-based cancer therapy developer Zymeworks Inc. rang the bell on the Toronto Stock Exchange, five weeks after its stock debuted in a $59-million (U.S.) initial public offering in Canada and on the New York Stock Exchange. It was by far the largest biotech IPO on a Canadian exchange in a decade and came on the heels of one of the largest stock offerings ever by a Canadian biotech firm, after dual-listed lupus-drug developer Aurinia Pharmaceuticals Inc. raised $150.5-million in March.

To continue reading this article, you must be a Globe Unlimited subscriber.

Subscribe to Globe Unlimited now!

Follow Sean Silcoff on Twitter: @SeanSilcoff

Trudeau says Ottawa wont legalize illicit drugs other than marijuana (The Canadian Press)

Discover content from The Globe and Mail that you might otherwise not have come across. Here well provide you with fresh suggestions where we will continue to make even better ones as we get to know you better.

You can let us know if a suggestion is not to your liking by hitting the close button to the right of the headline.

See the rest here:
Zymeworks IPO bears good tidings for Canadian biotechnology - The Globe and Mail

A post-secondary program in biotechnology opens doors to various careers in clinical research, DNA analysis, quality control and assurance, industrial microbiology and biochemistry, biology instrumentation and calibration. The graduates of this program demonstrate the ability to

Isolate, enumerate and identify microorganisms Collect and store samples Prepare specimen for staining Prepare microbiological media and reagents and culture pathogenic microbes Design and perform microbiology experiments Sample, measure, collect and analyze data Calibrate and use laboratory instruments Apply appropriate safety procedures Handle hazardous chemicals

The professionals can find employment in food, pharmaceutical and cosmetic industries as biotechnology technicians, lab technicians, biology lab assistants, life science lab technicians and instrumentation and calibration assistants. They can also work with companies into clinical research, quality testing and biotechnology product development.

Choosing a Biotechnology College in Canada

How you start your career depends on where you have studied, to a great extent. The biotechnology programs that have met the national technology accreditation requirements established by the Canadian Council of Technicians and Technologists (CCTT) and the Canadian Technology Accreditation Board (CTAB) offer better placement opportunities.

It is important to ask the following questions before enrolling into a biotechnology college or course in Canada:

Is the program accredited by the Canadian Technology Accreditation Board (CTAB)? Is the program affiliated to the Canadian Council of Technicians and Technologists (CCTT)? Does it combine laboratory work with classroom learning? Does the college allow you to apply for certification through the Ontario Association of Certified Engineering Technicians and Technologists for using the designation: Certified Technician? Does the program incorporate training in Occupational Health and Safety, HACCP, GMP or WHMIS to industry standards? Does the prospective college allow you to apply academic credits earned during the program to study for an advanced program? Does the program incorporate independent microbiology projects?

A program is worth considering if answer to all these questions is a yes. Centennial Colleges two-year post-secondary program in biotechnology meets all the above mentioned criteria. In addition, a special feature of the program is the project approach. It allows students to design independent projects to help them enhance their problem-solving and research approach. With this, the program is also a repeat recipient of the College Presidents Academic Program Recognition Award for outstanding student satisfaction.

Studying Biotechnology

The post-secondary diploma program in biotechnology typically runs for two years and covers a wide range of subjects. Students develop strong fundamentals in chemistry, inorganic chemistry, mathematics for applied science, and statistics for applied science, biotechnology, microbiology and technical report writing.

With this, they also study occupational health and safety, microbiology techniques, food microbiology, analytical chemistry, pharmaceutical microbiology and recombinant DNA technology. The program also lays a strong emphasis on computer education and covers microcomputer applications for technology A.

Enrolling in a Biotechnology Program

Students interested in applying for this program need to submit:

Secondary school diploma or equivalent English Grade 12 C or University or equivalent scores Mathematics Grade 11 M or 12 C or University or equivalent scores

Students currently in high school can also apply for this program. Their grades will be automatically transferred to the college.

Jason White, the author here gives an account of Biotechnology technician course at Centennial College. He further explains how the course helps the students to take up a career as lab assistants, quality testing and controlling assistants in pharmaceutical and cosmetic sectors.

Photo By HypnoArt from Pixabay

Visit link:
Tips to choose right Biotechnology College in Canada | Good Herald - Good Herald

Forests are under many threats, from new pests and pathogens, to invasive trees, to climate. The advancement of these traits by far exceeds the natural response of trees to acclimate, and outpaces the efforts to traditionally breed trees for forest conservation and restoration. Dr. Ellen V. Crocker is a postdoctoral researcher at the University of Kentucky. She talks about the current threats to forests including sudden oak death, chestnut blight and the emerald ash borer. She also discusses efforts in integrating new biotech tools in forest improvement, including genetic engineering, speed breeding, and gene drive approaches. Hosted by Dr. Paul Vincelli (@Pvincell).

Follow Dr. Crocker on Twitter@evcrocker

Follow Talking Biotech on Twitter@TalkingBiotech

FollowKevin Folta on Twitter @kevinfolta|Facebook:Facebook.com/kmfolta/| Lab website:Arabidopsisthaliana.com| All funding: Kevinfolta.com/transparency

Stitcher| iTunes|Player FM|TuneIn

Visit Kevin Foltas Talking Biotech

Visit link:
Talking Biotech: Can biotechnology help protect forests from pests, pathogens and climate change? - Genetic Literacy Project

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial (Translational Breast Cancer Research Consortium TBCRC 022) of Puma's investigational drug PB272 (neratinib) for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. The data were presented today in an oral presentation at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting in Chicago, Illinois.

The multicenter Phase II clinical trial enrolled patients with HER2-positive metastatic breast cancer who have brain metastases. The trial is being performed by the TBCRC and enrolled three cohorts of patients. Patients in the first cohort (n=40) included those with progressive brain metastases who were administered neratinib monotherapy. Data from this cohort were previously reported at the 2014 ASCO Annual Meeting and published in the Journal of Clinical Oncology in 2016. Patients in the second cohort (n=5) represent patients who had brain metastases which were amenable to surgery and who were administered neratinib monotherapy prior to and after surgical resection. The third cohort (target enrollment=60) enrolled two sub-groups of patients (prior lapatinib-treated and no prior lapatinib) with progressive brain metastases who were administered neratinib in combination with the chemotherapy drug capecitabine. The oral presentation reflects only the patients in the third cohort of patients without prior lapatinib exposure (cohort 3A, n=37), who all had progressive brain metastases at the time of enrollment and who received the combination of capecitabine plus neratinib. A full copy of the oral presentation that was presented at the ASCO Annual Meeting is available on the Puma Biotechnology website. Results from the second cohort and cohort 3B (prior lapatinib-treated) will be presented at a forthcoming medical meeting.

In cohort 3A, 30% of the patients had received prior craniotomy, 65% of the patients had received prior whole brain radiotherapy (WBRT), and 35% had received prior stereotactic radiosurgery (SRS) to the brain. No patients had received prior treatment with lapatinib.

The primary endpoint of the trial was central nervous system (CNS) Objective Response Rate according to a composite criteria that included volumetric brain MRI measurements, steroid use, neurological signs and symptoms, and RECIST evaluation for non-CNS sites. The secondary endpoint of the trial was CNS response by Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) Criteria. The efficacy results from the trial showed that 49% of patients experienced a CNS Objective Response by the composite criteria. The results also showed that the CNS response rate using the RANO-BM criteria was 24%. The median time to CNS progression was 5.5 months and the median overall survival was 13.5 months, though 49% of patients remain alive and survival data are immature.

The results for cohort 3A showed that the most frequently observed severe adverse event for the 37 patients evaluable for safety was diarrhea. Patients received antidiarrheal prophylaxis consisting of high dose loperamide, given together with the combination of capecitabine plus neratinib for the first cycle of treatment in order to try to reduce the neratinib-related diarrhea. Among the 37 patients evaluable for safety, 32% of the patients had grade 3 diarrhea and 41% had grade 2 diarrhea.

Neratinib given in combination with capecitabine showed promising activity in patients with heavily pre-treated HER2-positive disease metastatic to the CNS, said Rachel A. Freedman, MD, MPH, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute. Despite the introduction of several new treatments for patients with HER2-positive metastatic breast cancer, CNS progression events remain a major source of patient morbidity and mortality. Based on the results from TBCRC-022, we look forward to additional trials with neratinib-based regimens for HER2-positive CNS disease.

We are very pleased with the activity seen in this trial with the combination of neratinib plus capecitabine, said Alan H. Auerbach, CEO and President of Puma Biotechnology. As a small molecule that can cross the blood brain barrier, neratinib potentially offers patients with HER2-positive metastatic breast cancer that has metastasized to the CNS a novel HER2 targeted treatment option. We look forward to working with TBCRC on future trials of neratinib in patients with HER2-positive disease metastatic to the CNS.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidatesPB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2. Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the development and potential benefits of the Companys drug candidates, the Companys clinical trials and the announcement of data relative to these trials. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has no product revenue and no products approved for marketing, the Company's dependence on PB272, which is still under development and may never receive regulatory approval, the challenges associated with conducting and enrolling clinical trials, the risk that the results of clinical trials may not support the Company's drug candidate claims, even if approved, the risk that physicians and patients may not accept or use the Company's products, the Company's reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates, risks pertaining to securities class action, derivative and defamation lawsuits, the Company's dependence on licensed intellectual property, and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Visit link:
Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive ... - Business Wire (press release)

More and more students are taking up the course of Biotechnology these days. This is the direct result of the increased career opportunities that are now available to the students who have completed their M.Sc Biotechnology, or have just a B.Sc Biotechnology. There is also a growth in the number of BSc. Horticulture colleges, as this is yet another field, where the career opportunities are on a rise.

Whether you are seeking admission in B.Sc Horticulture colleges or want to do the course of M.Sc Biotechnology, you need to follow a prescribed path, in order to make a career for yourself in either of these two fields. The procedure that you need to follow, to make a career in the above fields, is as follows:

Bachelors Degree

The first step in the direction of finding a good job in the field of Biotechnology or Horticulture is to first complete a B.Sc Biotechnology degree or a Bachelors Degree in Horticulture. It is important that the decision to make a career in these fields is taken at the school stage itself, so that the students can complete their 10th and 12th class education in the Science stream and then take admission in good B.Sc Horticulture colleges or B.Sc Biotechnology colleges. There are numerous colleges present all over the world which offer really good bachelor courses in these two streams. The students can choose any college as per their liking and convenience.

Entrance Exams

The next stage is to get a specialized or masters degree in these two courses. In order to get admission into any college which offers a M.Sc Biotechnology or a Masters Degree in Horticulture, the students need to clear the entrance exams. Even in the case of undergraduate courses, some of the colleges conduct these entrance exams. However, mostly these entrance exams are for the specialized or masters courses only. These entrance exams are pretty tough in nature and the students need to be fully prepared in order to be able to clear the same.

Finding A Good Job

Once you have the Masters Degree in hand, then finding a suitable job for yourself becomes a piece of cake. With either of these degrees in hand, you can hope to get into any field like Agriculture, Animal Husbandry, Environmental Protection, Healthcare, Medicine, Genetic Engineering, Industrial Research and Development, etc. The career opportunities available to students of Biotechnology ad Horticulture are many. There are companies present in both the private as well as the public sector who need students specializing in these fields and are ready to offer very high pay packages in order to tempt the students to join their companies.

Therefore, if you are someone who wants to get into the field of Biotechnology or Horticulture, but are not sure about the future prospects of the same, then you need not worry. A simple study of the market will confirm to you that there are numerous opportunities that would be waiting for you once you have managed to successfully complete both your Bachelors as well as your Masters Degree in Biotechnology or Horticulture.

For more information about B.Sc Biotechnology visit http://bfitdoon.com/

Photo By PublicDomainPictures from Pixabay

Visit link:
Why Should You Complete Both BSc. Biotechnology And MSc. Biotechnology For A Good Career Opportune - Good Herald

Prof. Aurea Regina Telles Pupulin Universidade Estadual de Maring Brazil

The DDTWC 2013 was of great importance with respect to scientific discoveries and it was a well organized scientific program.

Dr. Uranchimeg Otoch National Cancer Center Mongolia

The DDTWC was a successful scientific program and a platform to meet numerous Nobel Laureates and some of the top international scientists. It was a great occasion to attend some stimulating lectures and poster presentations. Some of the highlights of the conference I observed were;

A. Administration. B. Scientifically motivating C. The venue. D. Social activities. E. Personal interaction of organizers with each participant.

Prof. Antonio Gotto, Jr. Lewis Thomas University USA

I found the Drug Discovery and Therapy World Congress 2013 to be an exceptionally well organized and scientifically stimulating conference. The lectures were very engaging, conducted at a high level, and exposed me to a wide variety of relevant topics in drug discovery and pharmacotherapy.

Dr. Nesrine Talaat Lamie Cairo University Egypt

I enjoyed the conference and the whole team.

1. The team was so friendly 2. The venue was nice and appealing. 3. The arrangement was good; however the schedule did not match with some speakers. 4. It was not clear for the poster presenter that there will be evaluation of the best poster on the last day of the conference. 5. The speakers did not cover my field of study (pharmaceutical analysis).

I was so pleased to meet some eminent scientists and the team.

Dr. Rathnam Chaguturu University of Kansas USA

"A fantastic conference of the highest caliber with ample opportunity to network with world-renowned scientists. A virtual 'high-five' to the conference organizers for their outstanding achievement in making this conference a grand success. I am already looking forward to next year's conference."

Dr. Frida Barak, Barzilai Medical Center Israel

Overall organization was very good; it was a scientifically stimulating event. The conference venue was also pleasing.

Prof. Illana Gozes, Tel Aviv University, Israel

It was a very nicely organized conference, in an excellent location, with excellent speakers and interesting interactions.

Dr. David Alexander Potter University of Minnesota United States

The "small meetings" within a meeting format allowed significant and meaningful scientific interactions.

Dr. J. O. Osayande Flanders Institute of Biotechnology Belgium

The conference was highly organized with respect to the venue and selection of presented scientific topics, if given another opportunity, I wouldnt mind joining the conference again in the upcoming years.

Dr. Ivor Cowlrick, Pharma Communications GmbH Germany

With regard to the congress: It was well organised with a challenging and far-reaching scientific agenda. The Hynes Convention Center in Boston is an excellent venue for any scientific congress. I did not attend any social activities but the colleagues were warm and receptive during the meeting.

Dr. Haya abdulwahab Abubshait University of Dammam Saudi Arabia

It was a pleasure attending the DDTWC; the congress was scientifically sound and fruitful in all respects. DDTWC was an excellent and successful event., It was a great opportunity for the scientists interested in various scientific fields and also to gain knowledge from the contributions of the eminent participants. It would be a pleasure to be part of the future conferences.

Dr. Denise de Oliveira Silva Instituto de Quimica da Universidade de So Paulo Brazil

It was a great honor to be one of the track-chairs and attend DDTWC in Boston in 2013. The high scientific level, the excellent organization, and the international standard venue located in a very pleasant city, made this a unique event. The high quality sessions promoted exciting discussions between researches from different fields, and led to productive interactions among participants and organizers, in a friendly atmosphere. Congratulations to the organizers!

Read more here:
Global Biotechnology Congress 2017

Application of technologies on biological systems, dead organisms and their derivatives and food and medicine can be broadly defined as biotechnology. It never had a particular definition since its applications and implementations on various other areas of science are enormous. From manipulating crops and plants to increase the yield to transfer of genes from one organism to the other biotechnology encompasses almost all the living and non-living entities on earth. With the drastic improvement in various machineries and equipments used in the processing of biological materials and the examining of microscopic organisms biotechnology has come a far way since the traditional days of fermentation like techniques, which also is a part of biotechnology.

In the earlier times, biotechnologys application was limited to agriculture and in the production of fermented food products but with the discovery of newer and much complicated data comprising of the most smallest of structures that are measured in microns biotechnology has been found fruitful in the production of many useful products that improves the quality of life of mankind. The categories of science like genetic engineering, animal cell culture, plant cell culture, microbiology, molecular biology, cytogenetics, cryopreservation, bioprocessing, biochemistry, cell biology, embryology, immunology and bioinformatics all these come under biotechnology.

Biotechnology has wide prospects when it comes to environmental science as well. It is used to recycle and retreat the wastes that are left behind at contaminated sites by various industries. This process is termed as bioremediation. Many experiments concerning DNA and RNA and other molecular structures in the human body also comprise of a wide area of practical biotechnology. Mapping of the genes has risen a lot of interest in this decade and with the completion of the Human Genome Project newer prospects for biotechnology has paved way.

Biotechnology has found promising applications in pharmaceutical manufacturing as well. From the production of antibiotics to the purification and separation processes for biomolecules. Biotechnology has its presence felt almost everywhere. Biotechnology plays a massive role in the field of medicine as well. As more and more genetic diseases are brought into picture it is through biotechnology that we try and find ways and means of manipulating the genes and discovering the cure for the disease.

Also with the depleting natural resources for fuel and the environmental effects caused by the use of the conventional fuels can be curbed to a certain extent with the proper manifestation of biotechnology in the production of biorenewable fuel from crops. Biotechnology can speed the production of ethanol and methane for natural gas from these crops.

Overall, biotechnology improves the quality of life and brings in new horizons of modern techniques in various aspects of human life.

The author of this article has great knowledge on Biotechnology. He has written many articles on Chromatography with the great knowledge. He has a great deal of knowledge in Pharmaceutical information as well.

Photo By qimono from Pixabay

Read the rest here:
Biotechnology: An Overview - Good Herald

Biotechnology experts say lack of collaboration in the face of limited resources will hamper the efficiency and effectiveness of the use and application of biotechnology in Nigeria.

The experts told the News Agency of Nigeria in separate interviews on Friday in Abuja that only synergy would help the nation achieve food security.

Dr Rufus Ebegba, the Director-General, National Biosafety Management Agency (NBMA), said that modern biotechnology was becoming increasingly important in addressing emerging food security, social and economic challenges.

With its perceived and real unintended consequences, regulatory agencies and stakeholders must unite with a sense of purpose, vision, mission and determination to ensure that our nation reap the benefits of biotechnology.

We have an excellent working relationship with, and Memorandums of Understanding with agencies like NAFDAC, SON, the Nigerian Customs Services, NABDA, ARCN, Ministries of Environment, Health and others.

We have been organising workshops and involved in seminars that encourages effective collaboration with other regulatory Ministries, Departments and Agencies (MDAs) on the use and application of biotechnology.

This is part of our effort to keep Nigerians abreast of laid down internationally accepted procedures for verification of GM foods and Feed Safety; and determine the future activities to build necessary capacity in the Nigeria biosafety regulatory system, he said.

He said that the agency had put in place world class measures, equipment and international arrangements that ensured the practice of modern biotechnology in Nigeria was one of the safest in the world.

Prof. Benjamin Ubi, the President, Biotechnology Society of Nigeria (BSN), said collaboration in the adoption of biotechnology would facilitate sustainable agricultural production in the country.

He said that the adoption of biotechnology applications was the panacea to the current food challenges facing the country.

Biotechnology, including genetic engineering and production of Genetically Modified Organisms (GMOs), provides powerful tools for the sustainable development of agriculture, fishery and forestry, as well as meeting the food needs of the population.

GMOs currently account for about 16 per cent of the worlds crops, particularly crops like soybean, maize, cotton and canola, and there are indications that the growing trend will continue.

So, we must eat what we grow and grow what we eat. This means we ought to produce more and agricultural biotechnology is a tool for achieving this, he said.

Ubi also pledged the support of the BSN for the efforts of National Biosafety Management Agency (NBMA) to harness the potential of modern biotechnology.

The rest is here:
Lack of collaboration hampers biotechnology effectiveness Experts - TheNewsGuru